logo
  

Takeda Pharma Partners With Zedira, Dr. Falk Pharma To Develop Therapy To Treat Celiac Disease

Takeda Pharmaceutical Company Limited (TKPHF.PK) Thursday announced partnership with Zedira and Dr. Falk Pharma GmbH to develop ZED1227/TAK-227, a Phase 2b investigational therapy to treat of celiac disease.

TAK-227 is designed to prevent the immune response to gluten in celiac disease, an autoimmune disease where the ingestion of gluten leads to inflammation and damage to the small intestine.

As per the deal, Takeda gets an exclusive license to develop and commercialize TAK-227 in the US, and other countries outside of Europe, Canada, Australia and China. Zedira and Falk Pharma will receive an upfront payment with milestone payments on achieving certain development, regulatory and commercial targets, as well as royalties on net sales.

In addition to TAK-227, Takeda is developing two other investigational celiac disease therapies that recently entered Phase 2 clinical trials, the company said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT